Outcomes with study treatment. (A) Best response among CLL/SLL patients by group. PD, progressive disease; SD, stable disease. *Four patients (17%) in group 3 developed PD while receiving ofatumumab monotherapy. (B) Forest plot of response rates by patient subgroups. (C) Median percent change in ALC from baseline by group. (D) Median percent change in the sum of the products of lymph node diameters (SPD) and ALC by group.